Given the high and selective expression of ACP3 in prostate cancer lesions,[30] the use of S‐A2855/B725 as tumor‐targeting moiety may lead to the development of radioligand theranostics for PCa with low uptake in salivary glands and kidney. This evidence concerns the gene ACP3 and posterior cortical atrophy.